Showing 3 posts of 3 posts found.

Takeda’s subcutaneous vedolizumab proves efficacious in Phase III trial for Ulcerative Colitis

October 22, 2018
Sales and Marketing Takeda, UC, biologic, phase III, results, ulcerative colitis, vedolizumab

Japanese pharma firm Takeda has announced that the gut-selective biologic vedolizumab when taken as a subcutaneous (SC) injection, proved efficacious …

FDA approves first-ever atopic dermatitis biologic treatment

March 31, 2017
Medical Communications, Sales and Marketing Dupixent, Regeneron, Sanofi, atopic dermatitis, biologic

Sanofi and Regeneron’s Dupixent (dupilumab) has become the first biologic medicine to be approved by the FDA for the treatment …


AZ’s first respiratory biologic meets primary endpoints in Phase III trials

September 5, 2016
Research and Development, Sales and Marketing AstraZeneca, asthma, benralizumab, biologic, respiratory, severe asthma

AstraZeneca has presented Phase III data at the European Respiratory Society (ERS) international congress which shows that trial biologic benralizumab …

Latest content